Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.51 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.48 |
| ▸ | GLS | O94925 | 1/20 | 0.48 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | FAAH | O00519 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | THRB | P10828 | 1/20 | 0.47 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.47 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13604586 | 0.90 | NR1H2 (0.49) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL1114093 | 0.90 | NR1H2 (0.49) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL14920966 | 0.90 | NR1H2 (0.49) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL30294023 | 0.90 | NR1H2 (0.49) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL561360 | 0.88 | HPGD (0.53) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL5946895 | 0.86 | GLS (0.49) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL15085735 | 0.86 | HPGD (0.57) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL561013 | 0.85 | GPR119 (0.54) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL6608848 | 0.85 | HPGD (0.53) | HPGDKDM4EPKMRECQLEPHX1 | |
| SCHEMBL26798387 | 0.85 | HPGD (0.61) | HPGDKDM4EPKMRECQLEPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1049 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-115724836-A | GPX4 protein degrading agent, preparation method and application thereof, and anti-tumor cell medicine | 北京大学 | 2023-03-03 | — | — | CN | claimed |
| CN-110981803-B | Anti-tumor compound and synthesis method and application thereof | 北京大学 | 2021-04-13 | — | — | CN | claimed |
| CN-104557868-A | Preparation method for quinoline derivatives | Hunan huateng pharmaceutical co ltd | 2015-04-29 | — | — | CN | claimed |
| US-20120157532-A1 | Method Of Treating Or Preventing A Convulsive Disorder In A Patient In Need Thereof | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2012-06-21 | — | — | US | claimed |
| US-20260144881-A1 | HPK1 TARGETING COMPOUNDS AND USES THEREOF | ARVINAS OPERATIONS, INC. (US) | 2026-05-28 | — | — | US | disclosed |
| US-12630530-B2 | FGFR inhibitor compound and use thereof | HENAN MEDINNO PHARMACEUTICAL TECHNOLOGY CO., LTD. (CN) | 2026-05-19 | — | — | US | disclosed |
| WO-2026102147-A1 | TETRAHYDROISOQUINOLINE HETEROBIFUNCTIONAL BCL-XL DEGRADERS | Treeline Biosciences, Inc. (US) | 2026-05-15 | — | — | WO | disclosed |
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2026-05-14 | — | — | US | disclosed |
| EP-4166557-B1 | INTERMEDIATES OF N-(3-(7H-PYRROLO[2,3-D]PYRIMIDIN-4-YL)PHENYL)BENZAMIDE DERIVATIVES | NOVARTIS AG (CH) | 2026-05-06 | — | — | EP | disclosed |
| EP-4731309-A1 | KRAS PROTEOLYSIS TARGETING CHIMERAS | Paq Therapeutics Inc. (US) | 2026-04-29 | — | — | EP | disclosed |
| EP-3886904-B1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS INC (US) | 2026-04-22 | — | — | EP | disclosed |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NUVATION BIO INC (US) | 2026-04-16 | — | — | US | disclosed |
| US-5773465-A | Tartronic acids, their acetalic ethers and o-esters | DOMPE FARMACEUTICI S.P.A. (IT) | 1998-06-30 | — | — | US | disclosed |
| WO-1997040051-A1 | FUSED IMIDAZOPYRIDINE DERIVATIVES AS ANTIHYPERLIPIDEMIC AGENTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1997-10-30 | — | — | WO | disclosed |
| US-5656656-A | Tartronic acids, their acetalic ethers and O-esters | DOMPE FARMACEUTICI S.P.A. (IT) | 1997-08-12 | — | — | US | disclosed |
| EP-0667850-B1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS | DOMPE FARMACEUTICI SPA (IT) | 1997-05-28 | — | — | EP | disclosed |
| EP-0771319-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | Takeda Chemical Industries, Ltd. (JP) | 1997-05-07 | — | — | EP | disclosed |
| WO-1996002542-A1 | TRICYCLIC COMPOUNDS, THEIR PRODUCTION AND USE | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1996-02-01 | — | — | WO | disclosed |
| EP-0667850-A1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS. | DOMPE FARMACEUTICI SPA (IT) | 1995-08-23 | — | — | EP | disclosed |
| WO-1994010127-A1 | TARTRONIC ACIDS, THEIR ACETALIC ETHERS AND O-ESTERS | DOMPE' FARMACEUTICI S.P.A. (IT) | 1994-05-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260132132-A1 | 3A,4,5,6-TETRAHYDRO-1 H-PYRAZOLO[3,4-C]PYRIDIN-7(7AH)-ONE DERIVATIVES AS FACTOR XIIA INHIBITORS | F11, F13B, F7 | HPGD 1576/4885KDM4E 2529/4885PKM 2662/4885 |
| US-20260144881-A1 | HPK1 TARGETING COMPOUNDS AND USES THEREOF | SGK1, PBK, SGK3 | HPGD 2936/4885KDM4E 1526/4885PKM 1053/4885 |
| US-12630530-B2 | FGFR inhibitor compound and use thereof | FGFR3, FGFR1, FGFR4 | HPGD 4078/4885KDM4E 1299/4885PKM 2578/4885 |
| US-20260102501-A1 | ANTI-CANCER NUCLEAR HORMONE RECEPTOR-TARGETING COMPOUNDS | NR5A1, NR5A2, NR3C1 | HPGD 2565/4885KDM4E 3467/4885PKM 4726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.